PBAC's latest decision on Vildagliptin: Recommended with restriction (2017). Considered for Treatment of type 2 diabetes mellitus in patients not adequately controlled on insulin therapy with or without metformin, for use in combination with insulin.
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
4
first 2010
Submissions
4
2010 → 2017
Eligible population
Adult patients with type 2 diabetes mellitus not adequately controlled on insulin therapy with or without metformin.
Therapy area
Endocrinology
Line of therapy
Later-line
Evidence base
RCT
Primary endpoint
HbA1c reduction
Pivotal trial size
694 patients
Key trials
Study 23138, Tang 2015, Study ADE07, Study 23135, Study 2311, Study 23137